Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
Go back to Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON| Stratcomm Media, Ltd. (NASDAQ: SMMT) | Delayed: 14.28 +0.53 (3.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.75 | 52 Week High | $19.75 | |||
| Open | $13.78 | 52 Week Low | $4.26 | |||
| Day High | $14.40 | P/E | N/A | |||
| Day Low | $13.70 | EPS | $0.00 | |||
| Volume | 7,392,225 | |||||
